Posaconazole: A New Agent for the Prevention and Management of Severe, Refractory or Invasive Fungal Infections
Posaconazole is the newest antifungal agent to be approved for use in Canada. With excellent in vitro activity against a broad spectrum of yeasts and filamentous fungi, as well as having a well-tolerated oral formulation, posaconazole offers many potential advantages. Of particular interest are its...
Saved in:
Main Authors: | Andrea V Page, W Conrad Liles |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2008-01-01
|
Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
Online Access: | http://dx.doi.org/10.1155/2008/825901 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful Use of Posaconazole to Treat Invasive Cutaneous Fungal Infection in a Liver Transplant Patient on Sirolimus
by: Randah Dahlan, et al.
Published: (2012-01-01) -
Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants
by: Santiago Grau, et al.
Published: (2015-10-01) -
Invasive Fungal Infections in Canada from 1992 to 1994
by: LE Nicolle, et al.
Published: (1998-01-01) -
Frequency and Treatment Outcome of Invasive Fungal Infections in Children with Hematological Malignancies
by: Rabiha Manzoor, et al.
Published: (2025-01-01) -
Mixed Fungal Infection (Aspergillus, Mucor, and Candida) of Severe Hand Injury
by: Milana Obradovic-Tomasev, et al.
Published: (2014-01-01)